ClinicalTrials.gg

Program

LM-2417

A development code.

In Sino Biopharmaceutical's pipeline, 41BBcondi/NaPi2b双抗. Its studies are led by Sino Biopharmaceutical.

Furthest: phase 2, since Nov 7, 20241 company-led study, 1 open or runningNext primary completion: Dec 25, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical11 open or runningphase 2since Nov 7, 2024Nov 7, 2024Dec 25, 2028phase 2 · NCT06682780
  • Named in Sino Biopharmaceutical’s own pipeline as LM-2417, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 7, 2024First study: phase 2 study in Advanced Solid TumorFirst studyNCT06682780 · 320 planned · China

Ahead

  1. Dec 25, 2028Primary completion: phase 2 study in Advanced Solid TumorNCT06682780

TargetBeta

“41BBcondi/NaPi2b双抗”the company's pipeline, read by Claude · source

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06682780Advanced Solid Tumor · China2RecruitingDec 25, 2028320

How it is read

Names in the registry

  • “LM-2417”, 1 entry

Codes read as this program: LM2417.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.